A Pharmacodynamic Study of SLM0807, HKB0701 and CJ30001 in Healthy Subject

NCT01380873 | Completed Phase 1

• 1 other identifier: CJ_VCM_103
• Study Type: interventional
• Target: 30
• Locations: 0 countries
• Sites: N/A

Brief Summary

This trial is conducted to

1. 1.assess whether SLM0807 alters pharmacodynamics of HKB0701
2. 2.estimate the pharmacodynamics of HKB0701 after multiple administration of CJ30001 and multiple co-administration of HKB0701/SLM0807 in healthy subject

Conditions

Diabetes Mellitus

Outcome Measures

Primary Outcomes (2)

• AUC0-2h of plasma glucose

  up to 2hrs

• △Cmax of plasma glucose

  up to 2hrs

Study Arms (3)

Group1

EXPERIMENTAL

Drug: Period I : HKB0701, Period II : HKB0701 and SLM0807, Period III : CJ30001

Group2

EXPERIMENTAL

Drug: Period I : HKB0701 and SLM0807, Period II : CJ30001, Period III : HKB0701

Group3

EXPERIMENTAL

Drug: Period I : CJ30001, Period II : HKB0701, Period III : HKB0701 and SLM0807

Interventions

Period I : HKB0701, Period II : HKB0701 and SLM0807, Period III : CJ30001 DRUG

Group1

Period I : HKB0701 and SLM0807, Period II : CJ30001, Period III : HKB0701 DRUG

Group2

Period I : CJ30001, Period II : HKB0701, Period III : HKB0701 and SLM0807 DRUG

Group3

Eligibility Criteria

• Age: 20 Years - 50 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy volunteers who are in age range of 20-50years and the weight range is not exceed ±20% of ideal weight. Ideal weight = \[height -100\]\*0.9
• Subjects with no history of any significant chronic disease
• Subjects with FPG\<100mg/dL and 2hr glucose after 75g OGTT\<140mg/dL
• Judged to be in good health on the basis of their vital sign, ECG, physical exam and routine laboratory data
• Available for the entire study period
• Willing to adhere to protocol requirements and sign a informed consent form

You may not qualify if:

• Subjects who have taken any drugs to induce or inhibit hepatic enzyme activity within 30days prior to drug administration
• Subjects who have symptom of an acute illness within 4 weeks prior to drug administration
• Subjects with a history of clinically significant allergies including drug allergies
• Subjects whose clinical laboratory test values are outside the accepted normal range(Especially,AST or ALT \>1.25 times to normal range or total bilirubin \> 1.5times to normal range)
• Subjects with a history of drug, caffeine abuse(caffeine drink \>5cups/day)
• Subjects with a history of alcohol abuse(alcohol\>30g/day) or who have ever drank alcohol within 7 days prior to drug administration
• Heavy smoker ( \>10cigarettes/day)
• Subjects who have had a diet known to interfere with the absorption, distribution, metabolism or excretion of drugs (especially, consumption of grapefruit juice)
• Subjects who have donated plasma within 60days prior to drug administration
• Subjects who have participated in a clinical study within 90days prior to drug administration
• Subjects who have received any drugs that might confound the results of the trial in the opinion of principal investigator within 10days prior to drug administration (cimetidine within 7days prior to drug administration)
• Female subjects who are pregnant, breastfeeding or not using medically acceptable birth control

Sponsors & Collaborators

• HK inno.N Corporation: lead

MeSH Terms

Conditions

Diabetes Mellitus

Condition Hierarchy (Ancestors)

Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Endocrine System Diseases

Study Officials

• Jae Gook Shin, MD, ph D

  Inje University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY

Study Record Dates

• First Submitted: June 1, 2011
• First Posted: June 27, 2011
• Study Start: January 1, 2010
• Primary Completion: February 1, 2010
• Study Completion: March 1, 2010
• Last Updated: June 27, 2011

Record last verified: 2011-06